Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1413 | Pituitary Clinical | ICEECE2012

Incidence of hypogonadism and evaluation of its impact on cardiovascular risk factors and quality of life in acromegalic patients

Rebora A , Nazzari E. , Malpassi D , Moretti S , Goglia U , Boschetti M , Minuto F , Ferone D

Acromegaly and hypogonadism represent independent cardiovascular risk factors, worsening either different metabolic parameters or quality of life (QoL).In our cohort of 41 acromegalic males (20–82 years), 35 resulted affected by hypogonadotropic hypogonadism, while only six were eugonadal. Twenty-nine out 35 had low testosterone levels at diagnosis and six developed a post-surgical hypogonadism (testosterone cut-off: 350 ng/dl). Among hypogonadal su...

ea0029p1750 | Thyroid cancer | ICEECE2012

Indoleamine 2,3-dioxygenase 1 (IDO1) and thyroid carcinoma: Ret/PTC appears as a strong genetic determinant for IDO1 expression

Menicali E. , Moretti S. , Voce P. , Melillo R. , Sponziello M. , Filetti S. , Avenia N. , Santoro M. , Puxeddu E.

Indoleamine 2,3-dioxygenase 1 (IDO1) is a single chain oxidoreductase that catalyzes tryptophan degradation to kynurenine. In cancer, it appears to exert an immunosuppressive function as part of an acquired mechanism of immune escape. In view of this notion, IDO1 has started to be considered a novel target in cancer therapy. Objective of this study was to evaluate IDO1 expression in papillary thyroid carcinoma (PTC) and to correlate its expression with genetic determinants of ...